Peptides for Weight Loss and Muscle Gain: Does Any of It Work? (2026)

"Peptides for weight loss and muscle gain" is the most commercially valuable phrase in this entire market, because it promises the one thing physiology makes hardest: losing fat and building muscle simultaneously. It is also the phrase with the widest gap between what is being sold and what has been demonstrated. This article closes that gap with the actual body-composition data rather than the mechanism stories.

Start with the finding that reorganises everything below. There is a peptide class that reliably produces large weight loss in humans — the incretin drugs — but the lean-mass side of the ledger runs in the wrong direction, and there is no peptide with controlled evidence of adding muscle while stripping fat in healthy, training adults. The compounds marketed hardest for "recomp" are the ones with the least human data of all. That is not a cynical framing; it is what happens when you read the body-composition literature instead of the sales page.

The recomp problem is physiological before it is pharmacological

Fat loss requires an energy deficit. Building muscle is easiest in an energy surplus. Doing both at once is not impossible, but it is constrained, and the constraint has been quantified.

A meta-analysis and meta-regression of randomised trials running resistance training in an energy deficit found that lean-mass gains were impaired compared with training without a deficit (effect size −0.57), while strength gains were statistically comparable between conditions. The meta-regression put a number on the tipping point: a deficit of roughly 500 kcal per day was enough to prevent gains in lean mass altogether¹.

Read that carefully, because two useful things fall out of it. First, in a deficit you can keep getting stronger while gaining little or no tissue — strength and hypertrophy are not the same outcome, and conflating them is how "I recomped" anecdotes get generated. Second, the size of the deficit is the lever. That is a dietary variable, not a pharmacological one, and it is the single most important input into the question this article is about.

The one class that actually moves weight — and what it costs

If you want a peptide with genuine randomised human weight-loss data, the incretin drugs are the only address. The numbers are large and replicated.

In STEP 1, 1,961 adults with overweight or obesity and without diabetes were randomised to once-weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. Mean body-weight change was −14.9% with semaglutide versus −2.4% with placebo, a treatment difference of −12.4 percentage points². In SURMOUNT-1, 2,539 adults received tirzepatide or placebo for 72 weeks; mean weight change was −15.0%, −19.5% and −20.9% at the 5 mg, 10 mg and 15 mg doses against −3.1% for placebo³. The investigational triple agonist retatrutide went further still in a phase 2 trial, reaching −24.2% at 48 weeks in the 12 mg group versus −2.1% on placebo⁴.

These are regulator-grade results and they are in a different universe from the animal data behind most "fat-loss peptides." But the question this page asks is about weight and muscle, and that requires looking at what the lost mass consisted of.

What the body-composition data actually show

A 2026 systematic review in Annals of Internal Medicine pulled together 35 randomised trials reporting body composition with liraglutide, semaglutide, tirzepatide or dulaglutide. Within the incretin arms, the median proportion of total weight loss attributable to muscle-based indices was 28.3% (interquartile range 15.9% to 39.9%), and about two thirds of studies exceeded the review's prespecified benchmark of roughly 25% for fat-free mass measured by bioimpedance or DXA⁵.

Three qualifications matter more than the headline number, and they are where most coverage of this finding goes wrong.

It is not unique to the drugs. The same review reported that among the 13 studies documenting weight loss in the lifestyle or placebo comparator groups, 38% also exceeded their respective benchmark⁵. Losing some lean tissue alongside fat is what weight loss does. The honest claim is that incretin-driven loss is larger in absolute terms and more often exceeds the benchmark — not that dieting is clean and drugs are not.

"Lean mass" is not "muscle." Fat-free mass as measured by bioimpedance or DXA includes water, glycogen and the connective and organ tissue that shrinks with a smaller body. A review of lean-mass changes with GLP-1-based therapies makes this point directly and notes how wide the reported range is across trials — from roughly 15% or less of total weight lost in some studies to 40–60% in others, driven by population, drug and measurement differences⁶. A single quoted percentage from a single trial is close to meaningless without knowing which method produced it.

Nobody measured whether it mattered. The Annals review flagged that no included study reported objective physical function outcomes⁵. So the clinically important question — does this lean-mass change make people weaker or more frail — is unanswered by the trial base, in either direction. Anyone telling you these drugs definitely wreck performance is going beyond the data just as much as anyone telling you they definitely don't.

So can an incretin drug be a "recomp" tool?

No, and the framing is the error. These are prescription medicines for obesity and type-2 diabetes. They work substantially by suppressing appetite, which means they deepen the energy deficit — the exact variable the training meta-analysis identified as what prevents lean-mass gain in the first place¹. A drug whose mechanism enlarges the deficit is structurally the wrong tool for adding tissue.

What the clinical literature actually recommends, when it addresses this, is mitigation rather than magic: reviews of strategies for minimising muscle loss during incretin therapy converge on adequate protein intake and resistance training as the levers, not a second drug⁷. That is the same advice the sports-nutrition literature gives someone dieting without any drug at all. It is unglamorous, it is free, and it is the only part of this whole page with strong evidence behind it.

If you are a lean, trained person considering one of these for physique reasons, understand that you are proposing an off-label use of a drug tested in people with a mean BMI of 38 — and that gastrointestinal adverse events are the dominant tolerability problem, with 4.5% of the semaglutide group in STEP 1 discontinuing for them versus 0.8% on placebo². We work through the wider safety picture in are peptides bad for you?.

The compounds sold *specifically* for recomp

Now the harder question: what about the peptides marketed explicitly for fat loss plus muscle gain, rather than the incretins that get repurposed into that pitch?

The GH-axis secretagogues — sermorelin, CJC-1295, ipamorelin, MK-677 — raise growth hormone and IGF-1 on a lab panel, which is real, and then fail to convert that into demonstrated body-composition benefit in healthy training people. We lay out that surrogate-marker gap in which muscle-growth peptides survive contact with the human trials and, for the fat side specifically, in peptides for fat loss. The growth-hormone fragments sold most aggressively for leaning out are worse off than that: AOD-9604's human obesity programme did not deliver, as we document in the AOD-9604 evidence review. And the "metabolic" compounds pitched at recomp directly — MOTS-c, 5-Amino-1MQ — run on rodent and cell data with no human body-composition trial at all, which is the whole argument of our MOTS-c evidence review and 5-Amino-1MQ evidence review.

There is no controlled trial in healthy, training adults showing any peptide simultaneously reducing fat mass and increasing muscle mass. When a vendor sells a "fat loss and muscle gain" stack, the product is a hypothesis with a price attached.

The parts nobody selling this will tell you

Two constraints apply regardless of which compound you land on.

Almost everything in the recomp category is not an FDA-approved product. Compounded peptides — including compounded semaglutide and tirzepatide — are not FDA-approved drugs, and the research-chemical tier is not a drug at all in any regulatory sense. The supply data on that market is genuinely alarming and we cover it in peptide injections for weight loss and in our guide to vendor red flags.

And if you compete under anti-doping rules, most of this is settled before the evidence discussion begins. The GH-axis peptides and the research-tier metabolic compounds are banned in tested sport, year-round, and a prescription does not change that. Our prohibited-substance checker gives a per-compound answer, and the WADA 2026 prohibited list for peptides explains how the classes catch compounds that are never named.

Where that leaves the question

The honest ranking is short. Incretin drugs produce the largest human weight loss ever recorded from a peptide, with roughly a quarter to a third of that loss coming from muscle-related indices — a proportion that also shows up, at smaller absolute scale, in people simply dieting. No peptide has been shown to add muscle while losing fat in healthy trained adults. The compounds marketed most confidently for that outcome have the thinnest human evidence in the whole category.

Which makes the practical answer slightly deflating and entirely defensible: the deficit size, the protein, and the training are what determine how much muscle survives a cut, and they are the only inputs with a meta-analysis behind them¹⁷. A drug can change how easy the deficit is to sustain. It cannot change what the deficit does to muscle, and nothing currently sold changes it in the direction the marketing claims.